About Nuclear receptor subfamily 6 group A member 1
Nuclear receptor subfamily 6 group A member 1 (NR6A1) is a protein
from Homo sapiens identified by UniProt accession
Q15406, 480 residues long.
MolForge cross-references it against 0 known binders and
40 disease associations.
Target properties
| Protein name | Nuclear receptor subfamily 6 group A member 1 |
| UniProt accession | Q15406 |
| Gene | NR6A1 |
| Organism | Homo sapiens |
| Length | 480 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (40)
Diseases linked to this target (Open Targets).
- age at menarche · score 0.26
- alcohol consumption measurement · score 0.17
- cutaneous melanoma · score 0.15
- brain aneurysm · score 0.12
- genetic disorder · score 0.12
- lung adenocarcinoma · score 0.10
- hepatocellular carcinoma · score 0.09
- body height · score 0.05
- neoplasm · score 0.05
- vital capacity · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15406-F1 | alphafold | PREDICTED | 76.97 | — |
Amino-acid sequence (480 residues)
MERDEPPPSG GGGGGGSAGF LEPPAALPPP PRNGFCQDEL AELDPGTISV SDDRAEQRTC LICGDRATGL HYGIISCEGC KGFFKRSICN KRVYRCSRDK NCVMSRKQRN RCQYCRLLKC LQMGMNRKAI REDGMPGGRN KSIGPVQISE EEIERIMSGQ EFEEEANHWS NHGDSDHSSP GNRASESNQP SPGSTLSSSR SVELNGFMAF REQYMGMSVP PHYQYIPHLF SYSGHSPLLP QQARSLDPQS YSLIHQLLSA EDLEPLGTPM LIEDGYAVTQ AELFALLCRL ADELLFRQIA WIKKLPFFCE LSIKDYTCLL SSTWQELILL SSLTVYSKQI FGELADVTAK YSPSDEELHR FSDEGMEVIE RLIYLYHKFH QLKVSNEEYA CMKAINFLNQ DIRGLTSASQ LEQLNKRYWY ICQDFTEYKY THQPNRFPDL MMCLPEIRYI AGKMVNVPLE QLPLLFKVVL HSCKTSVGKE
Explore Nuclear receptor subfamily 6 group A member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets